Apellis Pharmaceuticals
(NASDAQ) APLS
This security has been delisted. This page is retained for historical reference.
APLS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAPLS Financials
Key Financial Metrics (TTM)
Gross Margin
90.12%
Operating Margin
14.95%
Net Income Margin
12.06%
Return on Equity
39.71%
Return on Capital
6.47%
Return on Assets
12.31%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$996.12M
Operating Income
$165.22M
EBITDA
$180.14M
Operating Cash Flow
$37.77M
Capital Expenditure
$8.00K
Free Cash Flow
$37.78M
Cash & ST Invst.
$406.73M
Total Debt
$475.76M
Apellis Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$268.30M
+60.9%
Gross Profit
$227.46M
+71.7%
Gross Margin
84.78%
N/A
Market Cap
N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
N/A
N/A
Employees
705
N/A
Net Income
$18.66M
+120.2%
EBITDA
$29.76M
+137.0%
Quarterly Fundamentals
Total Cash
$406.73M
+13.5%
Total Debt
$475.76M
+1.3%
Accounts Receivable
$445.11M
+82.1%
Inventory
$131.41M
+59.3%
Long Term Debt
$375.05M
-18.9%
Short Term Debt
$100.71M
+1350.3%
Return on Assets
12.31%
N/A
Return on Invested Capital
20.68%
N/A
Free Cash Flow
-$60.97M
-14.1%
Operating Cash Flow
-$60.97M
-14.1%